Logo Medical XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business

Advertising options
  1. Home
  2. News
  3. sclerosis disease
Show results for
Products
Services
Software
Applications

Companies

News
Articles
Downloads
Videos

Refine by
Date

  • Older

Sclerosis Disease Articles & Analysis: Older

8 news found

Clinical benefits of exoskeletons

Clinical benefits of exoskeletons

Institut Guttmann (Badalona); Heidelberg University Hospital (Heidelberg), Asepeyo Hospital (Sant Cugat); CEN (European Center of Neurosciences) (Madrid); Vall d’Hebron Hospital (Barcelona); SIRN (Barcelona); Isidre Esteve Foundation (Sant Cugat); National Hospital for Paraplegics (Toledo); Association of Multiple Sclerosis and other neurological diseases ...

ByABLE Human Motion S.L.


Gesynta Pharma`s drug candidate GS-248 granted Orphan Drug Designation in US by the FDA for the treatment of systemic sclerosis

Gesynta Pharma`s drug candidate GS-248 granted Orphan Drug Designation in US by the FDA for the treatment of systemic sclerosis

Strengthened by this positive news and our constructive dialogue with the FDA, we continue working towards the goal of being able to offer an effective and safe treatment for patients with systemic sclerosis," says Patric Stenberg, CEO of Gesynta Pharma. Systemic sclerosis (also known as scleroderma) is a chronic, autoimmune disease that ...

ByGesynta Pharma AB


Qynapse Unveils its New Brand and Latest Developments in Neuroimaging AI Innovation at the 2021 RSNA Meeting in Chicago

Qynapse Unveils its New Brand and Latest Developments in Neuroimaging AI Innovation at the 2021 RSNA Meeting in Chicago

Qynapse will demo its flagship FDA-cleared and CE-marked neuroimaging solution, QyScore®, which combines MRI scans and AI to produce rapid, actionable insights into CNS disorders, such as Alzheimer’s disease, multiple sclerosis and Parkinson’s disease. “This year’s event represents a turning point in our product ...

ByQynapse


Avery Biomedical Devices’ Nextgen Diaphragm Pacing Transmitter, Spirit, Earns FDA Approval – Now Available

Avery Biomedical Devices’ Nextgen Diaphragm Pacing Transmitter, Spirit, Earns FDA Approval – Now Available

These adult and pediatric patients have chronic respiratory insufficiency due to conditions such as high spinal cord injuries (SCI), Congenital Hypoventilation Syndrome (CCHS), Central Sleep Apnea, Acute Flaccid Myelitis (AFM), various central neurological disorders, autoimmune diseases including Multiple Sclerosis and diseases caused by insect ...

ByAvery Biomedical Devices, Inc.


Haymarket Medical Network Launches Rare Disease Advisor

Haymarket Medical Network Launches Rare Disease Advisor

Haymarket Medical Network today launched Rare Disease Advisor, a new digital resource for healthcare professionals (HCPs) to help them recognize, diagnose, refer and treat rare diseases. ...

ByHaymarket Media Group


Phase II update: Gesynta Pharma announces significant progress across development program for first-in-class drug candidate GS-248

Phase II update: Gesynta Pharma announces significant progress across development program for first-in-class drug candidate GS-248

Coordinating Investigator Professor Ariane Herrick, The University of Manchester Centre for Musculoskeletal Research commented: "Systemic sclerosis is a chronic, autoimmune disease that leads to serious damage to the microvessels and which is associated with great unmet need. ...

ByGesynta Pharma AB


Gesynta Pharma initiates Phase II study of its first-in-class drug candidate GS-248 in patients with systemic sclerosis

Gesynta Pharma initiates Phase II study of its first-in-class drug candidate GS-248 in patients with systemic sclerosis

Gesynta Pharma AB today announced that the first patients have been dosed in a Phase II study of its oral drug candidate GS-248 in patients with systemic sclerosis - a debilitating autoimmune disease that causes serious damage to the microvasculature. ...

ByGesynta Pharma AB


Saneron and USF Patent Method for Umbilical Cord Blood Cell Use

Saneron and USF Patent Method for Umbilical Cord Blood Cell Use

Researchers at Saneron CCEL Therapeutics, Inc. of Tampa, Florida, (www.saneron-ccel.com) and the University of South Florida have received a patent relating to a method for obtaining and using umbilical cord blood cells from a donor or patient to provide neural cells for transplantation aimed at repairing a variety of neurodegenerative diseases of the brain and spinal cord, such ...

BySaneron CCEL Therapeutics, Inc.

  • Previous
  • Next
Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you
Back to top
About Medical XPRT

Medical XPRT is a global marketplace with solutions and suppliers for the medical sector, with product catalogs, articles, industry events, publications & more.

Channels

Solutions

  • Medical XPRT Industry Products
  • Medical XPRT Industry Software
  • Medical XPRT Industry Training
  • Medical XPRT Industry Services
  • Medical XPRT Industry Applications

Latest

  • Medical XPRT Industry News
  • Medical XPRT Industry Events

Publications

  • Medical XPRT Industry Articles
  • Medical XPRT Industry Books
  • Medical XPRT Industry Magazines
  • Medical XPRT Industry Downloads
  • Medical XPRT Industry Videos

Companies

  • Medical XPRT Industry Companies

  • FAQs
  • Company sitemap
  • Category sitemap
Medical XPRT is part of XPRT Media All Rights Reserved.
Terms
Privacy
  • Medical XPRT RSS List
Our sites:
Environmental XPRT
Agriculture XPRT
Energy XPRT
XPRT